Industry

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2022 financial and operating results on Thursday, August 11, 2022, following the close of the U.S. financial markets. Lineage management will also … [Read more…]

CPT code for emerging technology represents important milestone for therapeutic assessment and treatment of sports-related concussions. CLEVELAND–(BUSINESS WIRE)–TecTraum Inc., dedicated to providing the world’s first point-of-care treatment for concussions known as pro2cool®, announces today that the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code to help clinicians treat … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022, and invites investors to view the live … [Read more…]

The transatlantic regatta is the first stage of the three-year program Sailing into the Future. Together started by the Swiss pharmaceutical company, together with Alberto Bona. LA TRINITÉ-SUR-MER, France–(BUSINESS WIRE)–#IBSA–Latest-generation Class40, “scow” bow, five months of production: the IBSA craft with which Alberto Bona will participate in the Route du Rhum in November was launched … [Read more…]

Reports Revenue of $2.1 Billion, Growing 5%, and Net Income of $529 Million, or $1.12 per Diluted Share, Increasing 3% and 5%, Respectively, on a Reported Basis for Second Quarter 2022 Delivers 8% Operational Growth in Revenue and 9% Operational Growth in Adjusted Net Income for Second Quarter 2022 Reports Adjusted Net Income of $567 … [Read more…]

– LINZESS (Iinaclotide) EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year – – GAAP net income of $37 million and adjusted EBITDA of $56 million; ended Q2 2022 with $504 million in cash and cash equivalents – – Completes Board of Directors authorized share repurchase program; repays remaining principal amount of the 2022 … [Read more…]

CTP-543 Positive Topline Results Reported in THRIVE-AA1 and THRIVE-AA2 Phase 3 Studies in Alopecia Areata CTP-543 Has the Potential to Address an Important Unmet Need for a Large, Underserved Patient Population Conference Call Scheduled Today at 8:30 a.m. ET; Online Registration Required to Access Dial in and PIN for Live Call to Ask Questions LEXINGTON, … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m. ET. An audio webcast of the presentation will be available under the “Investors … [Read more…]

Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify CDT® Lung Nodule Test; Announced strategic arrangements during the quarter (Royal Philips, Memorial Sloan Kettering Cancer Center and Bio-Rad); Reaffirm 2022 revenue outlook of between $37.5 million and $39.5 million; Conference … [Read more…]

SEATTLE–(BUSINESS WIRE)–#earnings–NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences. 42nd Annual Canaccord Global Growth Conference Wednesday, August 10th Brad Gray, NanoString’s chief executive officer, will participate in a spatial biology panel titled, … [Read more…]